APR 14, 2017 11:31 AM PDT

New in Immunotherapy: Blocking Cancer Blood Vessels

WRITTEN BY: Kara Marker

Immunotherapy is a method of fighting cancer that revolves around empowering the immune system to reach its full cancer-killing potential. But tumor cells are constantly finding ways to resist and retaliate, so counterattacks are always necessary.

An antibody against ANGPT2 and VEGFA reprograms the tumor blood vessels to facilitate the extravasation of anti-tumoral T cells. Credit: Ella Maru Studio

A growing tumor generates its own system of blood vessels that flood cancer cells with oxygen and nutrients. In addition to providing nourishment, these vessels block the arrival of T cells either naturally sent by the immune system or sent as a result of an immunotherapy to boost T cell activity. Tumors rely on two key proteins to stimulate the growth of their blood vessel network and to keep T cells at bay: VEGFA and ANGPT2.

A new approach designed by experts from the Ecole Polytechnique Federale De Lausanne (EPFL) in Switzerland may be the answer: an antibody called A2V that simultaneously blocks VEGFA and ANGPT2 and metastasis.

"A2V not only regressed most of the tumor blood vessels, but also reversed the aberrant features of those that had remained, making them similar to normal blood vessels and more permissive to the arrival of anti-tumoral T cells,” explained study leader Michele De Palma.

By preventing tumors from reaping the benefits of their blood vessel system, A2V offers a new solution for treating many different types of cancer. However, the EPFL study showed that tumors were quick to answer back with a solution of their own: expression of protein PD-L1 that binds to PD-1 on the surface of T cells to prevent T cells from attacking. Thankfully, scientists have already developed antibodies that serve as checkpoint inhibitors to counter the PD-L1/PD-1 inhibition of T cells.

“Certain anti-angiogenic drugs, namely ANGPT2 inhibitors, have more profound effects on tumors than initially thought,” De Palma explained. “Besides targeting the blood vessels, they also help initiate anti-tumoral immune responses, which can be reinforced by immune checkpoint blockade.”

Based on De Palma’s findings, it seems that scientists are just unveiling the beginning of the potential benefits of applying the A2V antibody. Future studies will illustrate just how valuable this new approach will be for fighting cancer.

The present study was published in the journal Science Translational Medicine. For more on cancer immunotherapy, check out the video below: 

Sources: Ecole Polytechnique Federale De Lausanne (EPFL)

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 17, 2020
Immunology
Nervous Protein Neuromedin B May Prevent Immune Reactivity
AUG 17, 2020
Nervous Protein Neuromedin B May Prevent Immune Reactivity
A protein produced by the nervous system seems to play a role in regulating the immune system. For people with inflammat ...
OCT 17, 2020
Cell & Molecular Biology
Fat Droplets in Cells Help the Immune System Fight Infection
OCT 17, 2020
Fat Droplets in Cells Help the Immune System Fight Infection
Scientists have found that our immune system has a surprising helper: droplets of fat that sit inside cells.
OCT 26, 2020
Immunology
Gearing up for Life: The First 7 Days of the Immune System
OCT 26, 2020
Gearing up for Life: The First 7 Days of the Immune System
The mother’s placenta serves as a shield for the developing fetus inside the womb, protecting it from the constant ...
NOV 06, 2020
Immunology
The Coronavirus Is No Match Against Sybody 23
NOV 06, 2020
The Coronavirus Is No Match Against Sybody 23
The virus that causes COVID-19, SARS-CoV-2, uses its spike protein to gain access to cells, by binding to the ACE2 recep ...
NOV 17, 2020
Immunology
6 Injections a Year Prevent HIV Infections
NOV 17, 2020
6 Injections a Year Prevent HIV Infections
Last year, around 1.7 million people became infected with HIV, with around half of these being women. Encouraging result ...
NOV 17, 2020
Drug Discovery & Development
Antibiotics Before Age 2 Linked to Childhood Health Conditions
NOV 17, 2020
Antibiotics Before Age 2 Linked to Childhood Health Conditions
Researchers from Mayo Clinic have found a link between children aged two and under taking antibiotics and an increased r ...
Loading Comments...